[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100174996":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":10,"locations":10,"responsibleParty":23,"collaborators":10,"id":25,"slug":26,"hasResults":27,"nctId":28,"briefTitle":29,"officialTitle":29,"acronym":30,"eligibilityCriteria":31,"healthyVolunteers":27,"sex":32,"minAge":33,"maxAge":10,"enrollmentInfo":34,"targetDuration":10,"studyType":37,"phases":10,"briefSummary":38,"conditions":39,"keywords":10,"overallStatus":41,"whyStopped":10,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":50,"locationsCount":10},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Population of patients treated with Saxagliptin",null,[12],"Drug: Saxagliptin",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"DRUG","Saxagliptin","No Intervention",[9],[20],{"name":21,"affiliation":21,"role":22},"Bristol-Myers Squibb","STUDY_DIRECTOR",{"type":24,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100174996","description-of-drug-utilization-and-assessment-of-impact-of-saxagliptin-on-health-status-of-patients-with-type-2-diabetes-in-france-100174996",false,"NCT01552005","Description of Drug Utilization and Assessment of Impact of Saxagliptin on Health Status of Patients With Type 2 Diabetes in France","DIAPAZON","Inclusion Criteria:\n\n* Registry\n\n  * Patient ≥ 18 years old\n  * Patient with T2D\n* Ambispective Cohort\n\n  * Patient ≥ 18 years old\n  * Patient with T2D\n  * Patient initiated with Saxagliptin in the last 6 months before the inclusion or day of inclusion visit (whatever his\u002Fher ongoing hypoglycaemic treatment)\n  * Patient agreeing to participate, and not yet enrolled by another physician\n\nExclusion Criteria:\n\n* Patient participating in a clinical trial","ALL","18 Years",{"count":35,"type":36},1000,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to respond to The French Health Authority which has requested BMS France and Astra Zeneca (AZ) France to set-up a long-term cohort study in a representative sample of French Type 2 Diabetes mellitus (T2D) patients treated with Saxagliptin to generate real world data on drug utilization, joint population, non comparative effectiveness and safety",[40],"Type 2 Diabetes Mellitus (T2D)","COMPLETED","2016-06-06",{"date":44,"type":36},"2016-06-07",{"date":46,"type":10},"2012-05",{"date":48,"type":49},"2015-06","ACTUAL",{"name":5,"class":6}]